GlassScriptPhysician profile
Ramona Robinson
NPI 1164456679
$634.06
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $113 · 2021: $65.75 · 2022: $63.30.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $157.33 | 2019-2020 | |
| Novo Nordisk INC | $128.88 | 2019-2022 | |
| Allergan, INC. | $68.92 | 2019-2020 | |
| Horizon Therapeutics Plc | $56.44 | 2019-2020 | |
| Pfizer INC. | $50.93 | 2019 | |
| Merck Sharp & Dohme LLC | $40.90 | 2019 | |
| Glaxosmithkline, LLC. | $32.86 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.98 | 2021 | |
| Cranial Technologies, INC | $22.69 | 2020 | |
| Sanofi Pasteur INC. | $18.77 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.43 | 2019 | |
| Lilly USA, LLC | $11.93 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramona Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.